Novo Nordisk Inc Drug Patent Portfolio

Novo Nordisk Inc's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Novo Nordisk Inc News

Steering Through Challenges: Novo Nordisk Encounters a Crucial Year in 2026 - AD HOC NEWS

28 Jan, 2026

Lawsuits claim significant side effects from GLP-1 weight-loss medications - USA Today

28 Jan, 2026

Drug Manufacturers Invest Heavily in Lobbying for Weight-Loss Medications

27 Jan, 2026

Novo Nordisk or Viking: Which Obesity Treatment Stock is the More Secure Investment? - TradingView

27 Jan, 2026

See More